查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2044398

口服固態製劑市場預測至2034年－全球分析（按劑型、藥物釋放、給藥途徑、治療領域、生產流程、藥物類型、病患群體、最終用戶、分銷管道和地區分類）

Oral Solid Pharmaceuticals Market Forecasts to 2034 - Global Analysis By Dosage Form, Drug Release, Route of Administration, Therapeutic Area, Manufacturing Process, Drug Type, Patient Demographics, End User, Distribution Channel, and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 預測，到 2026 年，全球口服固態藥物市場規模預計將達到 5,857.5 億美元，在預測期內以 6.5% 的複合年成長率成長，到 2034 年將達到 9,694.1 億美元。

口服固態製劑是指以片劑、膠囊、粉末及顆粒劑等固態給藥的藥物。這些製劑因其穩定性好、易於操作、劑量精準且患者遵守用藥而廣受歡迎。口服固態製劑透過製粒、壓片和包衣等製程生產，可確保控制釋放和生物利用度。它們廣泛應用於從慢性病管理到急性病治療的各個治療領域。緩釋製劑和腸溶衣系統等製劑技術的進步不斷提高其療效和安全性，使口服固態製劑成為全球製藥業的基石。

慢性病盛行率增加

全球慢性疾病（如心血管疾病、糖尿病、呼吸系統疾病和癌症）的日益增多，推動了對能夠實現長期疾病管理的口服固態藥物的持續需求。對於需要每日或頻繁服藥的患者而言，片劑和膠囊的便利性和精確劑量具有顯著優勢。製藥公司正致力於開發複方製劑，將複雜的治療方案簡化為單一的固態劑型，從而提高患者的用藥依從性。隨著全球慢性疾病負擔的持續加重，可靠、可規模化生產且患者用藥方便的固態藥物仍然是全球製藥生產和醫療保健服務的基礎。

開發難溶性藥物的複雜性

藥物研發管線中湧現的大量新型化合物水溶性差，為口服固態製劑的開發帶來了巨大挑戰。製劑研發人員必須採用脂質體系統、奈米研磨和無定形固體分散體等先進技術才能達到足夠的生物利用度，這導致研發週期延長和生產成本增加。這些技術壁壘可能會延遲產品上市，或限制固態製劑在特定治療領域的應用。中小型製藥公司可能缺乏必要的設備和專業知識，從而在複雜候選藥物佔據主導地位的市場中限制其競爭力。

連續製造技術的擴展

在口服固態製劑生產中採用連續生產技術，在效率、品質和合規性方面帶來了變革性的機會。與傳統的間歇式生產不同，連續生產整合了即時監控和製程分析技術，能夠縮短生產週期、減少廢棄物並實現穩定的產品品質。監管機構正透過簡化核准流程來鼓勵這種生產方式。隨著製藥公司對老舊設施進行現代化改造，並解決疫情期間暴露出的供應鏈脆弱性問題，對片劑和膠囊連續生產平台的投資正在加速成長，這為技術供應商和契約製造組織（CMO）創造了巨大的發展機會。

來自其他劑型的競爭加劇

口溶錠、經皮吸收貼片、注射用生物製劑和液體製劑等替代給藥系統的日益普及，對傳統口服固態藥物構成了競爭。尋求更便利用藥、更快起效或解決吞嚥困難的患者可能更傾向於選擇這些替代給藥方式。兒童和老年人尤其推動了對非固態藥物的需求。此外，生物製藥革命也提高了人們對腸外給藥的重視程度，導致研發投資從傳統固態藥物平台轉移。如果固態藥物的創新無法跟上患者偏好和治療需求的變化，這種轉變可能會導致市場佔有率的萎縮。

新冠疫情的影響

新冠疫情為口服固態製劑市場帶來了挑戰與機會。初期封鎖措施擾亂了供應鏈，減少了門診就診量，暫時影響了慢性病治療藥物的研發。然而，用於治療新冠肺炎的口服抗病毒藥物的快速研發和供應，凸顯了口服固態製劑在對抗疫情中的關鍵作用。此次危機也加速了數位化醫療的普及，促進了電子處方箋和藥物宅配的發展。製藥公司透過製造地多元化和對先進生產技術的投資，增強了供應鏈的韌性，為後疫情時代醫療環境下市場的永續成長奠定了基礎。

在預測期內，「製藥公司」細分市場預計將佔據最大的市場佔有率。

預計在預測期內，製藥公司將佔據最大的市場佔有率，這主要得益於這些企業在藥品研發、生產和商業化過程中所扮演的核心角色。製藥公司在研發方面投入巨資，致力於開發創新口服固態製劑，例如複方組合藥物和用於治療難治性疾病的特效片劑。憑藉其完善的品管系統、豐富的監管經驗和廣泛的分銷網路，製藥公司在各個治療領域均保持領先地位。此外，製藥公司自主生產高價值固態製劑的趨勢持續發展，也確保了其在終端用戶對口服固態製劑技術和服務的需求方面繼續佔據主導地位。

在預測期內，線上藥局領域預計將呈現最高的複合年成長率。

在預測期內，線上藥局領域預計將呈現最高的成長率，這反映了醫療服務交付的快速數位轉型以及消費者對便捷取藥方式的偏好。患者擴大使用獲得許可的線上藥局進行慢性病治療藥物的宅配，以利用其具有競爭力的價格、自動配藥和私密服務等優勢。疫情永久改變了人們的購買習慣，即使實體藥局重新開業，許多消費者仍然傾向於選擇線上管道。重點市場加強遠端醫療和電子處方箋法規結構，進一步推動了這一管道的擴張。隨著數位健康生態系統的日趨成熟，線上藥局正成為固態藥品的首選分銷管道。

市佔率最大的地區

在預測期內，北美地區預計將佔據最大的市場佔有率，這得益於其成熟的製藥產業、完善的醫療保健基礎設施以及較高的患者健康意識。眾多跨國製藥公司、契約製造組織 (CMO) 和先進的研究機構的存在，推動了固態製劑技術的持續創新。優惠的醫保報銷政策和數位醫療工具的廣泛應用，也促進了全部區域處方藥消費的強勁成長。此外，人口老化以及心血管疾病和糖尿病等慢性病的高發生率，也持續推高了口服固態製劑的需求，從而鞏固了北美在整個預測期內的市場領先地位。

複合年成長率最高的地區

在預測期內，亞太地區預計將呈現最高的複合年成長率，這主要得益於醫療基礎設施的快速發展、藥品生產能力的擴張以及慢性病負擔的日益加重。中國、印度和韓國等國家正在崛起為全球固態製劑生產中心，吸引了大量投資用於尖端生產技術。政府推行的學名藥和全民健保措施正在改善民眾獲得基本口服固態製劑的機會。可支配收入的增加以及對便捷口服療法需求的成長進一步推動了市場成長。隨著跨國製藥公司在該地區擴大企業發展，亞太地區正鞏固其作為全球成長最快市場的地位。

免費客製化服務

所有購買此報告的客戶均可享受以下免費自訂選項之一。

  • 企業概況
    • 對其他市場參與企業（最多 3 家公司）進行全面分析
    • 對主要公司進行SWOT分析（最多3家公司）
  • 區域細分
    • 應客戶要求，我們提供主要國家的市場估算和預測，以及複合年成長率（註：需進行可行性檢查）。
  • 競爭性標竿分析
    • 透過產品系列、地域覆蓋和策略聯盟對標領先企業。

目錄

第1章執行摘要

  • 市場概覽及主要亮點
  • 促進因素、挑戰與機遇
  • 競爭格局概述
  • 戰略洞察與建議

第2章：研究框架

  • 研究目標和範圍
  • 相關人員分析
  • 研究假設和限制
  • 調查方法

第3章 市場動態與趨勢分析

  • 市場定義與結構
  • 主要市場促進因素
  • 市場限制與挑戰
  • 成長機會和重點投資領域
  • 工業威脅與風險評估
  • 技術與創新展望
  • 新興市場/高成長市場
  • 監管和政策環境
  • 新冠疫情的影響及復甦前景

第4章：競爭環境與策略評估

  • 波特五力分析
    • 供應商的議價能力
    • 買方的議價能力
    • 替代品的威脅
    • 新進入者的威脅
    • 競爭公司之間的競爭
  • 主要公司市佔率分析
  • 產品基準評效和效能比較

第5章 全球口服固態製劑市場：依劑型分類

  • 藥片
    • 速釋片
    • 咀嚼片
    • 發泡
    • 腸溶片
    • 膜衣錠
    • 口溶錠
  • 膠囊
    • 硬明膠膠囊
    • 軟膠囊
  • 粉末/顆粒
  • 錠劑和軟糖
  • 顆粒劑和迷你片劑
  • 口腔內崩壞膜
  • 其他

第6章 全球口服固態藥物市場：依藥物釋放類型分類

  • 立即發布
  • 修改版
  • 緩釋
  • 加長版
  • 控釋
  • 緩釋（腸溶包衣）
  • 標靶藥物遞送系統

第7章 全球口服固態藥物市場：依給藥途徑分類

  • 口服
  • 頰黏膜
  • 舌下

第8章 全球口服固態藥物市場：依治療領域分類

  • 心血管疾病
  • 腫瘤學
  • 中樞神經系統疾病
  • 抗感染藥物
  • 消化系統疾病
  • 呼吸系統疾病
  • 代謝性疾病
  • 疼痛管理
  • 其他治療領域

第9章 全球口服固態藥物市場：依生產流程分類

  • 直接壓縮
  • 濕式製粒
  • 乾式製粒
  • 擠出和球化
  • 塗層技術
  • 薄膜塗層
  • 糖霜
  • 腸溶衣

第10章 全球口服固態藥物市場：依藥物類型分類

  • 品牌藥品
  • 學名藥
  • 非處方藥

第11章 全球口服固態藥物市場：以病患群體分類

  • 成人
  • 兒童
  • 老年人

第12章 全球口服固態藥物市場：依最終用戶分類

  • 製藥公司
  • 合約研發生產組織（CDMO）
  • 研究機構

第13章 全球口服固態藥物市場：依通路分類

  • 醫院藥房
  • 零售藥房
  • 藥局
  • 網路藥房

第14章 全球口服固態藥物市場：依地區分類

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 荷蘭
    • 比利時
    • 瑞典
    • 瑞士
    • 波蘭
    • 其他歐洲國家
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳洲
    • 印尼
    • 泰國
    • 馬來西亞
    • 新加坡
    • 越南
    • 其他亞太國家
  • 南美洲
    • 巴西
    • 阿根廷
    • 哥倫比亞
    • 智利
    • 秘魯
    • 其他南美國家
  • 其他
    • 中東
      • 沙烏地阿拉伯
      • 阿拉伯聯合大公國
      • 卡達
      • 以色列
      • 其他中東國家
    • 非洲
      • 南非
      • 埃及
      • 摩洛哥
      • 其他非洲地區

第15章 策略市場資訊

  • 工業價值網路和供應鏈評估
  • 空白區域和機會地圖
  • 產品演進與市場生命週期分析
  • 通路、經銷商和打入市場策略的評估

第16章：產業趨勢與策略舉措

  • 併購
  • 夥伴關係、聯盟、合資企業
  • 新產品發布和認證
  • 擴大生產能力和投資
  • 其他策略舉措

第17章：公司簡介

  • Catalent Inc.
  • Lonza Group AG
  • Recipharm AB
  • Aenova Group
  • Thermo Fisher Scientific Inc.
  • Pfizer Inc.
  • Novartis AG
  • Roche Holding AG
  • Sun Pharmaceutical Industries Limited
  • Teva Pharmaceutical Industries Ltd.
  • Dr. Reddy's Laboratories Limited
  • Viatris Inc.
  • Sanofi SA
  • Abbott Laboratories
  • Bayer AG
  • GlaxoSmithKline plc
Product Code: SMRC36187

According to Stratistics MRC, the Global Oral Solid Pharmaceuticals Market is accounted for $585.75 billion in 2026 and is expected to reach $969.41 billion by 2034 growing at a CAGR of 6.5% during the forecast period. Oral solid pharmaceuticals refer to drug formulations administered in solid dosage forms such as tablets, capsules, powders, and granules. These formulations are widely preferred due to their stability, ease of handling, precise dosing, and patient compliance. Manufactured through processes like granulation, compression, and coating, oral solids ensure controlled drug release and bioavailability. They are extensively used across therapeutic areas, ranging from chronic disease management to acute treatments. Advances in formulation technologies, including sustained-release and enteric-coated systems, continue to improve efficacy and safety, making oral solid pharmaceuticals a cornerstone of the global pharmaceutical industry.

Market Dynamics:

Driver:

Increasing prevalence of chronic diseases

The global rise in chronic conditions such as cardiovascular disorders, diabetes, respiratory ailments, and cancer is fueling sustained demand for Oral Solid Pharmaceuticals that enable long-term disease management. Patients requiring daily or frequent medication regimens benefit from the convenience and precise dosing that tablets and capsules offer. Pharmaceutical companies are focusing on developing combination products that simplify complex treatment protocols into single solid dosage units, improving patient adherence. As the global burden of chronic diseases continues to escalate, the need for reliable, scalable, and patient-friendly solid formulations remains a cornerstone of pharmaceutical manufacturing and healthcare delivery worldwide.

Restraint:

Complexity in developing poorly soluble drugs

A significant proportion of new chemical entities emerging from drug discovery pipelines exhibit poor aqueous solubility, posing substantial challenges for Oral Solid Pharmaceuticals development. Formulators must employ advanced technologies such as lipid-based systems, nanomilling, and amorphous solid dispersions to achieve adequate bioavailability, increasing development timelines and manufacturing costs. These technical hurdles can delay product launches and limit the feasibility of solid formulations for certain therapeutic classes. Smaller pharmaceutical companies may lack the specialized equipment and expertise required, potentially restricting their ability to compete in markets dominated by complex drug candidates.

Opportunity:

Expansion of continuous manufacturing technologies

The adoption of continuous manufacturing in Oral Solid Pharmaceuticals production offers transformative opportunities for efficiency, quality, and regulatory compliance. Unlike traditional batch processing, continuous manufacturing integrates real-time monitoring and process analytical technology, enabling faster production cycles, reduced waste, and consistent product quality. Regulatory agencies are encouraging these approaches through streamlined approval pathways. As pharmaceutical companies seek to modernize aging facilities and respond to supply chain vulnerabilities exposed during the pandemic, investment in continuous manufacturing platforms for tablets and capsules is accelerating, creating significant growth opportunities for technology providers and contract manufacturing organizations.

Threat:

Intensifying competition from alternative dosage forms

The growing popularity of alternative drug delivery systems such as orally disintegrating tablets, transdermal patches, injectable biologics, and liquid formulations poses a competitive threat to traditional Oral Solid Pharmaceuticals. Patients seeking greater convenience, faster onset of action, or solutions for swallowing difficulties may prefer these alternatives. Pediatric and geriatric populations, in particular, drive demand for non-solid options. Additionally, the biologic drug revolution favors parenteral delivery, diverting research and development investment away from conventional solid platforms. This shift could erode market share if solid dosage innovation fails to keep pace with evolving patient preferences and therapeutic requirements.

Covid-19 Impact:

The COVID-19 pandemic created both disruptions and opportunities for the Oral Solid Pharmaceuticals market. Initial lockdowns caused supply chain interruptions and reduced outpatient visits, temporarily affecting prescription volumes for chronic medications. However, the rapid development and distribution of oral antivirals for COVID-19 treatment demonstrated the critical role of Oral Solid Pharmaceuticals in pandemic response. The crisis also accelerated digital health adoption, boosting e prescriptions and home delivery of medications. Pharmaceutical companies reinforced supply chain resilience by diversifying manufacturing sites and investing in advanced production technologies, positioning the market for sustained growth in the post-pandemic healthcare landscape.

The Pharmaceutical Companies segment is expected to be the largest during the forecast period

The Pharmaceutical Companies segment is expected to account for the largest market share during the forecast period, driven by the central role these organizations play in drug development, manufacturing, and commercialization. Pharmaceutical companies invest heavily in research and development to create innovative Oral Solid Pharmaceuticals, including fixed-dose combinations and specialty tablets for complex diseases. Their established quality systems, regulatory expertise, and extensive distribution networks enable them to maintain leadership across therapeutic categories. Additionally, the ongoing trend toward in-house manufacturing of high-value solid dosage products ensures that pharmaceutical companies continue to dominate end-user consumption of Oral Solid Pharmaceuticals technologies and services.

The Online Pharmacies segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the Online Pharmacies segment is predicted to witness the highest growth rate, reflecting the rapid digital transformation of healthcare delivery and consumer preference for convenient medication access. Patients increasingly turn to licensed e pharmacies for home delivery of chronic medications, benefiting from competitive pricing, automatic refills, and discreet service. The pandemic permanently shifted buying habits, with many consumers continuing to prefer online channels even after physical pharmacies reopened. Enhanced regulatory frameworks for telemedicine and e prescribing in major markets further support this channel's expansion. As digital health ecosystems mature, online pharmacies are becoming a preferred distribution route for solid dosage products.

Region with largest share:

During the forecast period, the North America region is expected to hold the largest market share, underpinned by a well-established pharmaceutical industry, strong healthcare infrastructure, and high patient awareness. The presence of numerous multinational pharmaceutical companies, contract manufacturing organizations, and advanced research institutions drives continuous innovation in solid dosage technologies. Favorable reimbursement policies and widespread adoption of digital health tools support robust prescription drug consumption across the region. Additionally, the aging population and high prevalence of chronic diseases such as cardiovascular conditions and diabetes create sustained demand for Oral Solid Pharmaceuticals, cementing North America's market leadership throughout the forecast period.

Region with highest CAGR:

Over the forecast period, the Asia Pacific region is anticipated to exhibit the highest CAGR, fueled by rapid healthcare infrastructure development, expanding pharmaceutical manufacturing capabilities, and growing chronic disease burden. Countries including China, India, and South Korea are emerging as global hubs for solid dosage production, attracting significant investment in modern manufacturing technologies. Government initiatives promoting generic medicines and universal healthcare coverage increase accessibility to essential Oral Solid Pharmaceuticals. Rising disposable incomes and growing patient populations seeking convenient oral therapies further drive market expansion. As multinational pharmaceutical companies expand their footprint in the region, Asia Pacific solidifies its position as the fastest-growing market.

Key players in the market

Some of the key players in Oral Solid Pharmaceuticals Market include Catalent Inc., Lonza Group AG, Recipharm AB, Aenova Group, Thermo Fisher Scientific Inc., Pfizer Inc., Novartis AG, Roche Holding AG, Sun Pharmaceutical Industries Limited, Teva Pharmaceutical Industries Ltd., Dr. Reddy's Laboratories Limited, Viatris Inc., Sanofi S.A., Abbott Laboratories, Bayer AG, and GlaxoSmithKline plc.

Key Developments:

In March 2026, Catalent announced a global partnership with GelMEDIX for the development and clinical manufacturing of iPSC-derived therapies, utilizing its advanced formulation expertise.

In March 2026, Thermo Fisher Scientific Inc. completed the acquisition of Clario Holdings, Inc., enhancing its clinical trial services and logistics for solid dosage medications globally.

In November 2025, Partnered with AstraZeneca Pharma India to distribute therapies for Hyperkalaemia, focusing on expanding the reach of critical solid dose treatments in emerging markets.

Dosage Forms Covered:

  • Tablets
  • Capsules
  • Powders & Granules
  • Lozenges & Pastilles
  • Pellets & Mini-Tablets
  • Orally Disintegrating Films
  • Other Dosage Forms

Drug Releases Covered:

  • Immediate Release
  • Modified Release
  • Sustained Release
  • Extended Release
  • Controlled Release
  • Delayed Release (Enteric-Coated)
  • Targeted Drug Delivery Systems

Route of Administrations Covered:

  • Oral
  • Buccal
  • Sublingual

Therapeutic Areas Covered:

  • Cardiovascular Diseases
  • Oncology
  • Central Nervous System (CNS) Disorders
  • Anti-Infectives
  • Gastrointestinal Disorders
  • Respiratory Diseases
  • Metabolic Disorders
  • Pain Management
  • Other Therapeutic Areas

Manufacturing Process Covered:

  • Direct Compression
  • Wet Granulation
  • Dry Granulation
  • Extrusion-Spheronization
  • Coating Technologies
  • Film Coating
  • Sugar Coating
  • Enteric Coating

Drug Types Covered:

  • Branded Drugs
  • Generic Drugs
  • Over-the-Counter (OTC) Drugs

Patient Demographics Covered:

  • Adult Population
  • Pediatric Population
  • Geriatric Population

End Users Covered:

  • Pharmaceutical Companies
  • Contract Development & Manufacturing Organizations (CDMOs)
  • Research Institutes

Distribution Channels Covered:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Drug Stores
  • Online Pharmacies

Regions Covered:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • United Kingdom
    • Germany
    • France
    • Italy
    • Spain
    • Netherlands
    • Belgium
    • Sweden
    • Switzerland
    • Poland
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Thailand
    • Malaysia
    • Singapore
    • Vietnam
    • Rest of Asia Pacific
  • South America
    • Brazil
    • Argentina
    • Colombia
    • Chile
    • Peru
    • Rest of South America
  • Rest of the World (RoW)
    • Middle East
      • Saudi Arabia
      • United Arab Emirates
      • Qatar
      • Israel
      • Rest of Middle East
    • Africa
      • South Africa
      • Egypt
      • Morocco
      • Rest of Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2023, 2024, 2025, 2026, 2027, 2028, 2030, 2032 and 2034
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

  • 1.1 Market Snapshot and Key Highlights
  • 1.2 Growth Drivers, Challenges, and Opportunities
  • 1.3 Competitive Landscape Overview
  • 1.4 Strategic Insights and Recommendations

2 Research Framework

  • 2.1 Study Objectives and Scope
  • 2.2 Stakeholder Analysis
  • 2.3 Research Assumptions and Limitations
  • 2.4 Research Methodology
    • 2.4.1 Data Collection (Primary and Secondary)
    • 2.4.2 Data Modeling and Estimation Techniques
    • 2.4.3 Data Validation and Triangulation
    • 2.4.4 Analytical and Forecasting Approach

3 Market Dynamics and Trend Analysis

  • 3.1 Market Definition and Structure
  • 3.2 Key Market Drivers
  • 3.3 Market Restraints and Challenges
  • 3.4 Growth Opportunities and Investment Hotspots
  • 3.5 Industry Threats and Risk Assessment
  • 3.6 Technology and Innovation Landscape
  • 3.7 Emerging and High-Growth Markets
  • 3.8 Regulatory and Policy Environment
  • 3.9 Impact of COVID-19 and Recovery Outlook

4 Competitive and Strategic Assessment

  • 4.1 Porter's Five Forces Analysis
    • 4.1.1 Supplier Bargaining Power
    • 4.1.2 Buyer Bargaining Power
    • 4.1.3 Threat of Substitutes
    • 4.1.4 Threat of New Entrants
    • 4.1.5 Competitive Rivalry
  • 4.2 Market Share Analysis of Key Players
  • 4.3 Product Benchmarking and Performance Comparison

5 Global Oral Solid Pharmaceuticals Market, By Dosage Form

  • 5.1 Tablets
    • 5.1.1 Immediate Release Tablets
    • 5.1.2 Chewable Tablets
    • 5.1.3 Effervescent Tablets
    • 5.1.4 Enteric-Coated Tablets
    • 5.1.5 Film-Coated Tablets
    • 5.1.6 Orally Disintegrating Tablets
  • 5.2 Capsules
    • 5.2.1 Hard Gelatin Capsules
    • 5.2.2 Soft Gelatin Capsules
  • 5.3 Powders & Granules
  • 5.4 Lozenges & Pastilles
  • 5.5 Pellets & Mini-Tablets
  • 5.6 Orally Disintegrating Films
  • 5.7 Other Dosage Forms

6 Global Oral Solid Pharmaceuticals Market, By Drug Release

  • 6.1 Immediate Release
  • 6.2 Modified Release
  • 6.3 Sustained Release
  • 6.4 Extended Release
  • 6.5 Controlled Release
  • 6.6 Delayed Release (Enteric-Coated)
  • 6.7 Targeted Drug Delivery Systems

7 Global Oral Solid Pharmaceuticals Market, By Route of Administration

  • 7.1 Oral
  • 7.2 Buccal
  • 7.3 Sublingual

8 Global Oral Solid Pharmaceuticals Market, By Therapeutic Area

  • 8.1 Cardiovascular Diseases
  • 8.2 Oncology
  • 8.3 Central Nervous System (CNS) Disorders
  • 8.4 Anti-Infectives
  • 8.5 Gastrointestinal Disorders
  • 8.6 Respiratory Diseases
  • 8.7 Metabolic Disorders
  • 8.8 Pain Management
  • 8.9 Other Therapeutic Areas

9 Global Oral Solid Pharmaceuticals Market, By Manufacturing Process

  • 9.1 Direct Compression
  • 9.2 Wet Granulation
  • 9.3 Dry Granulation
  • 9.4 Extrusion-Spheronization
  • 9.5 Coating Technologies
  • 9.6 Film Coating
  • 9.7 Sugar Coating
  • 9.8 Enteric Coating

10 Global Oral Solid Pharmaceuticals Market, By Drug Type

  • 10.1 Branded Drugs
  • 10.2 Generic Drugs
  • 10.3 Over-the-Counter (OTC) Drugs

11 Global Oral Solid Pharmaceuticals Market, By Patient Demographics

  • 11.1 Adult Population
  • 11.2 Pediatric Population
  • 11.3 Geriatric Population

12 Global Oral Solid Pharmaceuticals Market, By End User

  • 12.1 Pharmaceutical Companies
  • 12.2 Contract Development & Manufacturing Organizations (CDMOs)
  • 12.3 Research Institutes

13 Global Oral Solid Pharmaceuticals Market, By Distribution Channel

  • 13.1 Hospital Pharmacies
  • 13.2 Retail Pharmacies
  • 13.3 Drug Stores
  • 13.4 Online Pharmacies

14 Global Oral Solid Pharmaceuticals Market, By Geography

  • 14.1 North America
    • 14.1.1 United States
    • 14.1.2 Canada
    • 14.1.3 Mexico
  • 14.2 Europe
    • 14.2.1 United Kingdom
    • 14.2.2 Germany
    • 14.2.3 France
    • 14.2.4 Italy
    • 14.2.5 Spain
    • 14.2.6 Netherlands
    • 14.2.7 Belgium
    • 14.2.8 Sweden
    • 14.2.9 Switzerland
    • 14.2.10 Poland
    • 14.2.11 Rest of Europe
  • 14.3 Asia Pacific
    • 14.3.1 China
    • 14.3.2 Japan
    • 14.3.3 India
    • 14.3.4 South Korea
    • 14.3.5 Australia
    • 14.3.6 Indonesia
    • 14.3.7 Thailand
    • 14.3.8 Malaysia
    • 14.3.9 Singapore
    • 14.3.10 Vietnam
    • 14.3.11 Rest of Asia Pacific
  • 14.4 South America
    • 14.4.1 Brazil
    • 14.4.2 Argentina
    • 14.4.3 Colombia
    • 14.4.4 Chile
    • 14.4.5 Peru
    • 14.4.6 Rest of South America
  • 14.5 Rest of the World (RoW)
    • 14.5.1 Middle East
      • 14.5.1.1 Saudi Arabia
      • 14.5.1.2 United Arab Emirates
      • 14.5.1.3 Qatar
      • 14.5.1.4 Israel
      • 14.5.1.5 Rest of Middle East
    • 14.5.2 Africa
      • 14.5.2.1 South Africa
      • 14.5.2.2 Egypt
      • 14.5.2.3 Morocco
      • 14.5.2.4 Rest of Africa

15 Strategic Market Intelligence

  • 15.1 Industry Value Network and Supply Chain Assessment
  • 15.2 White-Space and Opportunity Mapping
  • 15.3 Product Evolution and Market Life Cycle Analysis
  • 15.4 Channel, Distributor, and Go-to-Market Assessment

16 Industry Developments and Strategic Initiatives

  • 16.1 Mergers and Acquisitions
  • 16.2 Partnerships, Alliances, and Joint Ventures
  • 16.3 New Product Launches and Certifications
  • 16.4 Capacity Expansion and Investments
  • 16.5 Other Strategic Initiatives

17 Company Profiles

  • 17.1 Catalent Inc.
  • 17.2 Lonza Group AG
  • 17.3 Recipharm AB
  • 17.4 Aenova Group
  • 17.5 Thermo Fisher Scientific Inc.
  • 17.6 Pfizer Inc.
  • 17.7 Novartis AG
  • 17.8 Roche Holding AG
  • 17.9 Sun Pharmaceutical Industries Limited
  • 17.10 Teva Pharmaceutical Industries Ltd.
  • 17.11 Dr. Reddy's Laboratories Limited
  • 17.12 Viatris Inc.
  • 17.13 Sanofi S.A.
  • 17.14 Abbott Laboratories
  • 17.15 Bayer AG
  • 17.16 GlaxoSmithKline plc

List of Tables

  • Table 1 Global Oral Solid Pharmaceuticals Market Outlook, By Region (2023-2034) ($MN)
  • Table 2 Global Oral Solid Pharmaceuticals Market Outlook, By Dosage Form (2023-2034) ($MN)
  • Table 3 Global Oral Solid Pharmaceuticals Market Outlook, By Tablets (2023-2034) ($MN)
  • Table 4 Global Oral Solid Pharmaceuticals Market Outlook, By Immediate Release Tablets (2023-2034) ($MN)
  • Table 5 Global Oral Solid Pharmaceuticals Market Outlook, By Chewable Tablets (2023-2034) ($MN)
  • Table 6 Global Oral Solid Pharmaceuticals Market Outlook, By Effervescent Tablets (2023-2034) ($MN)
  • Table 7 Global Oral Solid Pharmaceuticals Market Outlook, By Enteric-Coated Tablets (2023-2034) ($MN)
  • Table 8 Global Oral Solid Pharmaceuticals Market Outlook, By Film-Coated Tablets (2023-2034) ($MN)
  • Table 9 Global Oral Solid Pharmaceuticals Market Outlook, By Orally Disintegrating Tablets (2023-2034) ($MN)
  • Table 10 Global Oral Solid Pharmaceuticals Market Outlook, By Capsules (2023-2034) ($MN)
  • Table 11 Global Oral Solid Pharmaceuticals Market Outlook, By Hard Gelatin Capsules (2023-2034) ($MN)
  • Table 12 Global Oral Solid Pharmaceuticals Market Outlook, By Soft Gelatin Capsules (2023-2034) ($MN)
  • Table 13 Global Oral Solid Pharmaceuticals Market Outlook, By Powders & Granules (2023-2034) ($MN)
  • Table 14 Global Oral Solid Pharmaceuticals Market Outlook, By Lozenges & Pastilles (2023-2034) ($MN)
  • Table 15 Global Oral Solid Pharmaceuticals Market Outlook, By Pellets & Mini-Tablets (2023-2034) ($MN)
  • Table 16 Global Oral Solid Pharmaceuticals Market Outlook, By Orally Disintegrating Films (2023-2034) ($MN)
  • Table 17 Global Oral Solid Pharmaceuticals Market Outlook, By Other Dosage Forms (2023-2034) ($MN)
  • Table 18 Global Oral Solid Pharmaceuticals Market Outlook, By Drug Release (2023-2034) ($MN)
  • Table 19 Global Oral Solid Pharmaceuticals Market Outlook, By Immediate Release (2023-2034) ($MN)
  • Table 20 Global Oral Solid Pharmaceuticals Market Outlook, By Modified Release (2023-2034) ($MN)
  • Table 21 Global Oral Solid Pharmaceuticals Market Outlook, By Sustained Release (2023-2034) ($MN)
  • Table 22 Global Oral Solid Pharmaceuticals Market Outlook, By Extended Release (2023-2034) ($MN)
  • Table 23 Global Oral Solid Pharmaceuticals Market Outlook, By Controlled Release (2023-2034) ($MN)
  • Table 24 Global Oral Solid Pharmaceuticals Market Outlook, By Delayed Release (Enteric-Coated) (2023-2034) ($MN)
  • Table 25 Global Oral Solid Pharmaceuticals Market Outlook, By Targeted Drug Delivery Systems (2023-2034) ($MN)
  • Table 26 Global Oral Solid Pharmaceuticals Market Outlook, By Route of Administration (2023-2034) ($MN)
  • Table 27 Global Oral Solid Pharmaceuticals Market Outlook, By Oral (2023-2034) ($MN)
  • Table 28 Global Oral Solid Pharmaceuticals Market Outlook, By Buccal (2023-2034) ($MN)
  • Table 29 Global Oral Solid Pharmaceuticals Market Outlook, By Sublingual (2023-2034) ($MN)
  • Table 30 Global Oral Solid Pharmaceuticals Market Outlook, By Therapeutic Area (2023-2034) ($MN)
  • Table 31 Global Oral Solid Pharmaceuticals Market Outlook, By Cardiovascular Diseases (2023-2034) ($MN)
  • Table 32 Global Oral Solid Pharmaceuticals Market Outlook, By Oncology (2023-2034) ($MN)
  • Table 33 Global Oral Solid Pharmaceuticals Market Outlook, By Central Nervous System (CNS) Disorders (2023-2034) ($MN)
  • Table 34 Global Oral Solid Pharmaceuticals Market Outlook, By Anti-Infectives (2023-2034) ($MN)
  • Table 35 Global Oral Solid Pharmaceuticals Market Outlook, By Gastrointestinal Disorders (2023-2034) ($MN)
  • Table 36 Global Oral Solid Pharmaceuticals Market Outlook, By Respiratory Diseases (2023-2034) ($MN)
  • Table 37 Global Oral Solid Pharmaceuticals Market Outlook, By Metabolic Disorders (2023-2034) ($MN)
  • Table 38 Global Oral Solid Pharmaceuticals Market Outlook, By Pain Management (2023-2034) ($MN)
  • Table 39 Global Oral Solid Pharmaceuticals Market Outlook, By Other Therapeutic Areas (2023-2034) ($MN)
  • Table 40 Global Oral Solid Pharmaceuticals Market Outlook, By Manufacturing Process (2023-2034) ($MN)
  • Table 41 Global Oral Solid Pharmaceuticals Market Outlook, By Direct Compression (2023-2034) ($MN)
  • Table 42 Global Oral Solid Pharmaceuticals Market Outlook, By Wet Granulation (2023-2034) ($MN)
  • Table 43 Global Oral Solid Pharmaceuticals Market Outlook, By Dry Granulation (2023-2034) ($MN)
  • Table 44 Global Oral Solid Pharmaceuticals Market Outlook, By Extrusion-Spheronization (2023-2034) ($MN)
  • Table 45 Global Oral Solid Pharmaceuticals Market Outlook, By Coating Technologies (2023-2034) ($MN)
  • Table 46 Global Oral Solid Pharmaceuticals Market Outlook, By Film Coating (2023-2034) ($MN)
  • Table 47 Global Oral Solid Pharmaceuticals Market Outlook, By Sugar Coating (2023-2034) ($MN)
  • Table 48 Global Oral Solid Pharmaceuticals Market Outlook, By Enteric Coating (2023-2034) ($MN)
  • Table 49 Global Oral Solid Pharmaceuticals Market Outlook, By Drug Type (2023-2034) ($MN)
  • Table 50 Global Oral Solid Pharmaceuticals Market Outlook, By Branded Drugs (2023-2034) ($MN)
  • Table 51 Global Oral Solid Pharmaceuticals Market Outlook, By Generic Drugs (2023-2034) ($MN)
  • Table 52 Global Oral Solid Pharmaceuticals Market Outlook, By Over-the-Counter (OTC) Drugs (2023-2034) ($MN)
  • Table 53 Global Oral Solid Pharmaceuticals Market Outlook, By Patient Demographics (2023-2034) ($MN)
  • Table 54 Global Oral Solid Pharmaceuticals Market Outlook, By Adult Population (2023-2034) ($MN)
  • Table 55 Global Oral Solid Pharmaceuticals Market Outlook, By Pediatric Population (2023-2034) ($MN)
  • Table 56 Global Oral Solid Pharmaceuticals Market Outlook, By Geriatric Population (2023-2034) ($MN)
  • Table 57 Global Oral Solid Pharmaceuticals Market Outlook, By End User (2023-2034) ($MN)
  • Table 58 Global Oral Solid Pharmaceuticals Market Outlook, By Pharmaceutical Companies (2023-2034) ($MN)
  • Table 59 Global Oral Solid Pharmaceuticals Market Outlook, By Contract Development & Manufacturing Organizations (CDMOs) (2023-2034) ($MN)
  • Table 60 Global Oral Solid Pharmaceuticals Market Outlook, By Research Institutes (2023-2034) ($MN)
  • Table 61 Global Oral Solid Pharmaceuticals Market Outlook, By Distribution Channel (2023-2034) ($MN)
  • Table 62 Global Oral Solid Pharmaceuticals Market Outlook, By Hospital Pharmacies (2023-2034) ($MN)
  • Table 63 Global Oral Solid Pharmaceuticals Market Outlook, By Retail Pharmacies (2023-2034) ($MN)
  • Table 64 Global Oral Solid Pharmaceuticals Market Outlook, By Drug Stores (2023-2034) ($MN)
  • Table 65 Global Oral Solid Pharmaceuticals Market Outlook, By Online Pharmacies (2023-2034) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Rest of the World (RoW) Regions are also represented in the same manner as above.